First Patient Worldwide Works With St. Luke's for Advanced Kidney Cancer Immunotherapy Study
St. Luke’s University Health Network Accrues First Patient Globally for Phase 3 Fully Personalized Cancer Immunotherapy Study for Advanced Kidney Cancer
Sanjiv Agarwala, MD serves as principal investigator for innovative ADAPT Phase 3 Study
Dr. Sanjiv Agarwala
Bethlehem, PA (2/27/2013) - Dr. Sanjiv Agarwala, Chief of Medical Oncology and Hematology for St. Luke's University Health Network, has accrued the first patient worldwide for the ADAPT Phase 3 Kidney Cancer Study, a randomized, multicenter clinical trial, that may hold promise for patients with advanced, or metastatic, renal cell carcinoma (mRCC).
RCC is the most common type of kidney cancer with about 50,000 newly diagnosed cases each year. The ADAPT study, using an investigational fully personalized immunotherapy called AGS-003, has shown the potential to extend overall survival for patients with aggressive, advanced stage disease. Average survival with standard treatment ranges from six months to two years.
The fully personalized therapy, AGS-003, is made using ribonucleic acid (RNA) extracted from a patient’s tumor, following surgical removal, along with that patient’s white blood cells. This cell-based treatment is designed to trigger the body’s natural immune response to help recognize and kill cancer cells. In the ADAPT Phase 3 Study, AGS-003is combined with the available standard targeted drug therapy sunitinib.
“This study is truly exciting as previous AGS-003 studies have shown very promising results,” says Dr. Agarwala. AGS-003 has been shown in clinical studies to successfully stimulate an immune response against tumor cells and has been associated with improved survival. In the Phase 2 study, treatment with AGS-003 plus sunitinib nearly doubled overall survival compared to historical results of unfavorable risk patients treated with sunitinab alone. Greater than 50 percent of patients in the study survived longer than 30 months after initiating therapy.
AGS-003 has very low toxicity compared to other cancer therapies because it is developed primarily from the patient’s own blood cells and is designed to trigger a natural immune response.
To be considered for the ADAPT study patients must be 18 or older and newly diagnosed with clear cell mRCC. Patients must be good candidates for standard tumor removal surgery and for treatment with standard targeted drug therapy, starting with sunitinib (Sutent®).
If you are interested in participating in this investigational clinical study through St. Luke’s Cancer Center, please call the study coordinator Rose Cabral at 484-503-4151.
To learn more about advanced kidney cancer, immunotherapy or the ADAPT study, visit www.ADAPTKidneyCancer.com or find it on Twitter @ADAPTkdnycancer.
The ADAPT study is being sponsored by Argos Therapeutics, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform.
About Dr. Agarwala
Dr. Agarwala is an internationally recognized investigator in the field of melanoma and immunotherapy. He presents nationally and internationally on melanoma and is a member of the Melanoma Core Committee of the Eastern Cooperative Oncology Group (ECOG). In addition, he is a Professor of Medicine, Temple University School of Medicine, Philadelphia, PA.
Dr. Agarwala has published a variety of therapeutic approaches to melanoma and has led promising clinical trials in immunotherapy and targeted therapy of melanoma. He co-authored the book “Melanoma: Translational Research and Emerging Therapies” to help bridge the gap between research and clinical approaches to melanoma therapy.
Director, Marketing & Public Relations
St. Luke’s University Health Network